Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Dec 2024 value amounting to $570,000.

  • Arcutis Biotherapeutics' Other Non-Current Liabilities fell 14.29% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $360,000, marking a year-over-year decrease of 14.29%. This contributed to the annual value of $570,000 for FY2024, which is 32.86% down from last year.
  • Arcutis Biotherapeutics' Other Non-Current Liabilities amounted to $570,000 in FY2024, which was down 32.86% from $849,000 recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Other Non-Current Liabilities registered a high of $849,000 during FY2023, and its lowest value of $25,000 during FY2021.
  • In the last 2 years, Arcutis Biotherapeutics' Other Non-Current Liabilities had a median value of $709,500 in 2023 and averaged $709,500.
  • Data for Arcutis Biotherapeutics' Other Non-Current Liabilities shows a maximum YoY crashed of 69.51% (in 2021) over the last 5 years.
  • Over the past 4 years, Arcutis Biotherapeutics' Other Non-Current Liabilities (Yearly) stood at $82,000 in 2020, then crashed by 69.51% to $25,000 in 2021, then reached $849,000 in 2023, then plummeted by 32.86% to $570,000 in 2024.